Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
Both receptors couple to Gs proteins and activate adenylyl cyclase, raising intracellular cAMP in beta cells and triggering insulin exocytosis in a glucose-dependent manner
Get your custom peptide protocol: Tailored to your body and goals Precise dosing and cycle length Safe stacking combinations Backed by peer-reviewed studies Ready in under 2 minutes The Verdict: Retatrutide Wins on Trial Data, Zepbound Wins on Availability Retatrutide produced the largest average weight loss reported in a Phase 2 obesity trial to date, but it cannot be legally prescribed for weight loss as of June 2026
Losing and maintaining more than 10% of body weight is associated with significant reductions in obesity-related complications, including hypertension, type 2 diabetes, and heart disease
growing healthcare awareness and stronger emphasis on targeted treatments are helping adoption of personalized medicine across diabetes and obesity use cases
US$ 26.57
US$ 20.16
US$ 20.04
US$ 23.76
US$ 22.91
